598 related articles for article (PubMed ID: 25517451)
1. Role of 2-[18F] fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography in the post-therapy surveillance of breast cancer.
Chang HT; Hu C; Chiu YL; Peng NJ; Liu RS
PLoS One; 2014; 9(12):e115127. PubMed ID: 25517451
[TBL] [Abstract][Full Text] [Related]
2. Detection of resectable recurrences in colorectal cancer patients with 2-[18F]fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography.
Peng NJ; Hu C; King TM; Chiu YL; Wang JH; Liu RS
Cancer Biother Radiopharm; 2013; 28(6):479-87. PubMed ID: 23713869
[TBL] [Abstract][Full Text] [Related]
3. Impact of 18F-FDG PET/CT in the management decisions of breast cancer board on early-stage breast cancer.
Özdemir A; Güven M; Binici S; Uygur S; Toktaş O
Clin Transl Oncol; 2024 May; 26(5):1139-1146. PubMed ID: 37848693
[TBL] [Abstract][Full Text] [Related]
4. Validation of FDG uptake in the arterial wall as an imaging biomarker of atherosclerotic plaques with 18F-fluorodeoxyglucose positron emission tomography-computed tomography (FDG-PET/CT).
Bucci M; Aparici CM; Hawkins R; Bacharach S; Schrek C; Cheng S; Tong E; Arora S; Parati E; Wintermark M
J Neuroimaging; 2014; 24(2):117-23. PubMed ID: 22928741
[TBL] [Abstract][Full Text] [Related]
5. Maximum standardized uptake value on 18F-fluoro-2-deoxy-glucose positron emission tomography/computed tomography and glucose transporter-1 expression correlates with survival in invasive ductal carcinoma of the pancreas.
Kitasato Y; Yasunaga M; Okuda K; Kinoshita H; Tanaka H; Okabe Y; Kawahara A; Kage M; Kaida H; Ishibashi M
Pancreas; 2014 Oct; 43(7):1060-5. PubMed ID: 25121413
[TBL] [Abstract][Full Text] [Related]
6. Preoperative PET/CT in early-stage breast cancer.
Bernsdorf M; Berthelsen AK; Wielenga VT; Kroman N; Teilum D; Binderup T; Tange UB; Andersson M; Kjær A; Loft A; Graff J
Ann Oncol; 2012 Sep; 23(9):2277-2282. PubMed ID: 22357250
[TBL] [Abstract][Full Text] [Related]
7. Anisakiasis mimics cancer recurrence: two cases of extragastrointestinal anisakiasis suspected to be recurrence of gynecological cancer on PET-CT and molecular biological investigation.
Nogami Y; Fujii-Nishimura Y; Banno K; Suzuki A; Susumu N; Hibi T; Murakami K; Yamada T; Sugiyama H; Morishima Y; Aoki D
BMC Med Imaging; 2016 Apr; 16():31. PubMed ID: 27112922
[TBL] [Abstract][Full Text] [Related]
8. Use of positron emission tomography in surgery follow-up of esophageal cancer.
Teyton P; Metges JP; Atmani A; Jestin-Le Tallec V; Volant A; Visvikis D; Bail JP; Pradier O; Lozac'h P; Cheze Le Rest C
J Gastrointest Surg; 2009 Mar; 13(3):451-8. PubMed ID: 19023632
[TBL] [Abstract][Full Text] [Related]
9. Comparison of FDG-PET/CT for Cancer Detection in Populations With Different Risks of Underlying Malignancy.
Chan HP; Liu WS; Liou WS; Hu C; Chiu YL; Peng NJ
In Vivo; 2020; 34(1):469-478. PubMed ID: 31882515
[No Abstract] [Full Text] [Related]
10.
Jaeger ZJ; Williams GA; Chen L; Mhlanga JC; Cornelius LA; Fields RC
J Surg Oncol; 2022 Mar; 125(3):525-534. PubMed ID: 34741547
[TBL] [Abstract][Full Text] [Related]
11. Impact of 18-fluorodeoxyglucose positron emission tomography on the management of pancreatic cancer.
Izuishi K; Yamamoto Y; Sano T; Takebayashi R; Masaki T; Suzuki Y
J Gastrointest Surg; 2010 Jul; 14(7):1151-8. PubMed ID: 20443074
[TBL] [Abstract][Full Text] [Related]
12. The role of PET/CT for evaluating breast cancer.
Yang SK; Cho N; Moon WK
Korean J Radiol; 2007; 8(5):429-37. PubMed ID: 17923786
[TBL] [Abstract][Full Text] [Related]
13. Women's Health Update: Growing Role of PET for Patients with Breast Cancer.
Ulaner GA; Vaz SC
Semin Nucl Med; 2024 Mar; 54(2):247-255. PubMed ID: 38365547
[TBL] [Abstract][Full Text] [Related]
14. Predicting location of recurrence using FDG, FLT, and Cu-ATSM PET in canine sinonasal tumors treated with radiotherapy.
Bradshaw T; Fu R; Bowen S; Zhu J; Forrest L; Jeraj R
Phys Med Biol; 2015 Jul; 60(13):5211-24. PubMed ID: 26083082
[TBL] [Abstract][Full Text] [Related]
15. Clinical value of [
Zheng J; Yang Y; Ke H; Qian R; Liu Z; Miao W
Eur J Radiol; 2023 Dec; 169():111170. PubMed ID: 37925813
[TBL] [Abstract][Full Text] [Related]
16. Role of 18F-FDG PET/CT in patients without known primary malignancy with skeletal lesions suspicious for cancer metastasis.
Park SB; Park JM; Moon SH; Cho YS; Sun JM; Kim BT; Lee KH
PLoS One; 2018; 13(5):e0196808. PubMed ID: 29746513
[TBL] [Abstract][Full Text] [Related]
17. Utility of ¹⁸fluoro-deoxyglucose positron emission tomography for prognosis and response assessments in a phase 2 study of romidepsin in patients with relapsed or refractory peripheral T-cell lymphoma.
Horwitz S; Coiffier B; Foss F; Prince HM; Sokol L; Greenwood M; Caballero D; Morschhauser F; Pinter-Brown L; Iyer SP; Shustov A; Nichols J; Balser J; Balser B; Pro B
Ann Oncol; 2015 Apr; 26(4):774-779. PubMed ID: 25605745
[TBL] [Abstract][Full Text] [Related]
18. Metabolic Positron Emission Tomography in Breast Cancer.
Cecil K; Huppert L; Mukhtar R; Dibble EH; O'Brien SR; Ulaner GA; Lawhn-Heath C
PET Clin; 2023 Oct; 18(4):473-485. PubMed ID: 37369614
[TBL] [Abstract][Full Text] [Related]
19. Current Role and Future Prospects of Positron Emission Tomography (PET)/Computed Tomography (CT) in the Management of Breast Cancer.
Robson N; Thekkinkattil DK
Medicina (Kaunas); 2024 Feb; 60(2):. PubMed ID: 38399608
[TBL] [Abstract][Full Text] [Related]
20. Contrast-enhanced [18 F] fluorodeoxyglucose-positron emission tomography/computed tomography in clinical oncology: tumor-, site-, and question-based comparison with standard positron emission tomography/computed tomography.
Morbelli S; Conzi R; Campus C; Cittadini G; Bossert I; Massollo M; Fornarini G; Calamia I; Marini C; Fiz F; Ghersi C; Derchi LE; Sambuceti G
Cancer Imaging; 2014 Apr; 14(1):10. PubMed ID: 25609564
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
